article · Microbes and Infectious Diseases /Microbes and Infectious Diseases
Background: Klebsiella pneumoniae has two different pathotypes: hypervirulent Klebsiella pneumoniae (hvkp) and classical Klebsiella pneumoniae (ckp), hvkp is more potent than ckpcausing vast types of severe disseminated infections. Aim of the work: This cross sectional study doneto detect frequency of hvkp versus ckp , their antibiotic resistance and risk factors associated with their infections. Methods: samples were collected from admitted patients cultured on MacConkey agar, pink colonies were confirmed to be Klebsiella pneumonia and sensitivity were done by vitek 2. String test was done forhypermucoviscosityand PCR to detect virulence genes. Results: 100 samples were collectedfrom 2020 to 2023, 64of them revealedhvkp which were isolated from old age with mean± SD of62.7±20.5, most of isolates were from ICU from pneumonia patients. There wasa significant difference in ceftriaxone, cefoxitin, gentamycin and tobramycin resistance between hvkp, ckp with p value 0.03, 0.04 , 0.01 and 0.02 respectively, 24% of hvkp strains were ESBL producers.Fourteen (14%) were Pandrug resistant, 14(14%) were extremely drug resistant and 36 (36%) were multidrug resistant.iuc A was the most frequent virulence gene 62% followed by fimH (42%). Diabetes mellitus, hypertension and cardiovascular disease were the most significant risk factors associated with hvkp infection. Conclusion:hvkp is a serious pathogen that utilizes a battery of virulence factors for survival and pathogenesis, also has an ability to acquire drug resistance through transfer of genetic material,so we have to shed light on new strategies to improve diagnosis,treatment and prevention of hvkp causing infections.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21608/mid.2024.272832.1823
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.